Nvidia beat at $81.6B and fell. The Fed split 8-4. Oil dropped below $100. Every headline eased. Every constraint held.

THE DAILY PULSE

Everything eased. Nothing resolved.

The Dow jumped 645 points. The S&P rose over 1%. The Nasdaq gained over 1.5%.

Oil dropped over 5% to $98. First close below $100 in weeks. The 10-year eased to near 4.65%. The VIX fell to 17.

Gold held flat. The dollar softened.

The surface read like an exhale. Equities rallied. Yields pulled back. Energy cracked.

Then the FOMC minutes landed at 2 p.m. Nvidia reported after the bell. Samsung cut a deal near midnight.

Every headline eased. The question is what the market actually bought.

PREMIER FEATURE

Hidden in Tesla's Filing: A $12 Billion "Super Startup"

Pull up Tesla's most recent SEC filing. Page 5.

And you'll see a single line showing $12 billion in revenue from a brand-new "super startup" Elon Musk has been quietly incubating inside Tesla.

But it sits at the center of what Blackstone calls "a $23 trillion investment opportunity."

And on July 22, Elon is expected to pull back the curtain and reveal exactly what he's building.

But Adam O'Dell already knows… and he reveals it all in this urgent video.

THE LEAD SIGNAL

Nvidia beat on every line. The stock fell anyway.

Nvidia (NVDA) posted $81.6B in revenue. That beat by over $2B. Data center hit $75.2B. Earnings topped estimates at $1.87.

Q2 guidance cleared the bar too. Revenue guided near $91B. The street expected $87B. The company announced $80B in buybacks.

The stock still fell roughly 2% after hours. This is the fourth straight post-earnings fade.

The issue is not demand. Huang called it "parabolic."

Polymarket prices only about a 30% chance NVDA reaches $240 this month. Downside bets gained share after the print.

The chip passed the earnings test. It has not passed the access test.

The Access Wall

Demand was never the question this quarter. Access was. The market repriced Nvidia from a growth story into a gatekeeping story. The gate sits in Beijing. That changes what the beat is worth.

THE ARCHITECTURE

The Fed just published its most divided meeting in three decades.

The April minutes showed an 8-4 vote to hold. That is the widest split since 1992.

Three dissenters wanted the easing bias removed. One pushed for a cut. The rate held. The direction did not.

Kalshi prices zero cuts in 2026 near 70%. One cut sits under 20%. The hike path is building. A hike before 2028 sits near 75%. Before 2027 is at 36%.

Inflation is running above 3%. CPI and PPI confirmed the oil pass-through. Energy-driven inflation is the core debate inside the committee.

Kevin Warsh takes his first meeting in mid-June. He inherits a committee four members already wanted to move.

The Divided Baseline

The rate path is no longer stuck. It is contested. Four members voted against the hold. That shifts what patience means at the Fed. The baseline the market assumed is the one four voters rejected.

FROM OUR PARTNERS

The 7 Stocks Built to Outlast the Market

Some stocks are built for a quarter… others for a lifetime.

Our 7 Stocks to Buy and Hold Forever report reveals companies with the strength to deliver year after year - through recessions, rate hikes, and even the next crash.

One is a tech leader with a 15% payout ratio - leaving decades of room for dividend growth. 

Another is a utility that’s paid every quarter for 96 years straight. 

And that’s not all - we’ve included 5 more companies that treat payouts as high priority.

These are the stocks that anchor portfolios and keep paying.

This is your chance to see all 7 names and tickers - from a consumer staples powerhouse with 20 years of outperformance to a healthcare leader with 61 years of payout hikes. 

THE CROSS-CURRENTS

Three constraints eased in headline. None eased in structure.

Oil dropped over 5% to $98 on Hormuz hopes. But Polymarket shows normalization by end of May at only 5%. Over $17M in volume backs that view. Tankers crossing is not flows restored.

Samsung averted a 47,000-worker strike with a last-minute deal. DRAM prices are up near 90% this quarter. The agreement is tentative. Deeper divisions remain.

The U.S.-China summit ended without chip export progress. Semis sold off. H200 access is still blocked.

All three share a pattern. The headline cleared. The supply chain did not.

The Headline Discount

The market bought the pause in each constraint. Oil paused below $100. Samsung paused the walkout. Diplomacy paused the chip wall. A pause is not a resolution. The discount sits in what happens when they expire.

THE FORETELL LENS

The rally priced relief. The minutes priced something else.

Wednesday was the strongest session in weeks. It landed the same day. The Fed published its deepest divide in decades.

Oil dropped on hope. Not on ships. Nvidia beat and fell. Samsung settled under government pressure.

The relief rally carries a hidden assumption. Time solves these constraints.

The FOMC minutes say time may cost more now. Warsh inherits a hawkish split with oil near $100. The discount rate keeps climbing. That moves against every asset the rally just bought.

The easing was real. Resolution requires confirmation that constraints are clearing. Not just pausing.

The Assumption Underneath

Relief is not resolution. The market treated Wednesday as proof the pressure lifts. The minutes showed four voters who want it to tighten. The gap between those reads is where the next move sits.

PARTNER SPOTLIGHT

Florida Is Testing New Alternative Pesticide

Med-X is moving toward a possible Nasdaq listing (ticker: MXRX) - and once that happens, the early window closes.

Before Wall Street prices it in, Med-X has already generated $6.4M in sales, placed Nature-Cide on Amazon.com, Walmart.com, and Kroger.com, and begun expanding into 41+ global markets.

Florida's mosquito control districts-America's most well-funded and influential-are independently testing Nature-Cide botanical pesticides, as Med-X pursues WHO pre-qualification for global public health adoption.

This is the gap before the bell.

Review the Med-X opportunity now - before Nasdaq plans unfold.

 

Disclosures:This is a paid advertisement for Med-X's Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com

FINAL FRAME

Wednesday gave the market a full menu of relief.

Oil below $100. A clean Nvidia beat. A Samsung deal. Softer yields. A lower VIX.

None of it changed the rate path. None of it reopened the Strait. None of it unlocked China.

The constraints are structural. The relief was temporal.

Capital moves early. Coverage catches up. The gap between the two is worth watching.

Keep Reading